Omeros

Omeros is a biotechnology company that develops and commercializes innovative pharmaceuticals and therapeutics, with a focus on orphan diseases and other areas of unmet medical need, similar to companies like Gilead Sciences, Biogen, and Amgen. The company's pipeline includes products for the treatment of various conditions, including hematologic malignancies, inflammatory disorders, and central nervous system disorders, which are also areas of research for institutions like the National Institutes of Health and the University of California, San Francisco. Omeros has collaborations with organizations such as the Fred Hutchinson Cancer Research Center and the University of Washington, and its products have been recognized by awards such as the Fast Track designation from the US Food and Drug Administration. The company's work is also related to the research of scientists like James Allison and Tasuku Honjo, who were awarded the Nobel Prize in Physiology or Medicine.

Introduction

Omeros is a publicly traded company listed on the NASDAQ stock exchange, with its headquarters located in Seattle, Washington, near other biotechnology companies like ZymoGenetics and ICOS Corporation. The company was founded in 1994 by Gregory A. Demopulos, who serves as the company's chairman and chief executive officer, and has a similar background to other biotechnology executives like Herb Boyer and Robert Swanson. Omeros has a diverse pipeline of products, including OMIDRIA (phenylephrine and ketorolac injection), which is used in cataract surgery and glaucoma surgery, and has been studied in clinical trials at institutions like the University of California, Los Angeles and the Baylor College of Medicine. The company's products are also related to the work of organizations like the American Academy of Ophthalmology and the National Eye Institute.

History

Omeros was founded in 1994 by Gregory A. Demopulos, who had previously worked at companies like Microsoft and Boeing, and has a similar entrepreneurial background to other biotechnology founders like Craig Venter and William Rastetter. The company began its operations in Seattle, Washington, and initially focused on the development of pharmaceuticals for the treatment of various diseases, including cancer and inflammatory disorders, which are also areas of research for institutions like the Sloan-Kettering Institute and the University of Texas Southwestern Medical Center. In 2010, Omeros completed an initial public offering (IPO) and listed its shares on the NASDAQ stock exchange, similar to other biotechnology companies like Genentech and Chiron Corporation. The company has since expanded its operations and has established collaborations with organizations like the National Cancer Institute and the University of Oxford.

Products

Omeros has a diverse pipeline of products, including OMIDRIA (phenylephrine and ketorolac injection), which is used in cataract surgery and glaucoma surgery, and has been studied in clinical trials at institutions like the University of California, San Francisco and the Duke University School of Medicine. The company is also developing products for the treatment of hematologic malignancies, such as acute myeloid leukemia and myelodysplastic syndrome, which are also areas of research for institutions like the Memorial Sloan-Kettering Cancer Center and the University of Pennsylvania. Omeros has collaborations with organizations like the Leukemia & Lymphoma Society and the American Cancer Society, and its products have been recognized by awards such as the Breakthrough Therapy designation from the US Food and Drug Administration. The company's work is also related to the research of scientists like Brian Druker and Nicholas Lydon, who developed the tyrosine kinase inhibitor imatinib.

Research and Development

Omeros has a strong research and development program, with a focus on the development of innovative pharmaceuticals and therapeutics for the treatment of various diseases, including orphan diseases and other areas of unmet medical need, similar to companies like Genzyme and BioMarin Pharmaceutical. The company has collaborations with organizations like the National Institutes of Health and the University of California, Berkeley, and its research has been published in scientific journals like the New England Journal of Medicine and the Journal of Clinical Oncology. Omeros is also developing products for the treatment of inflammatory disorders, such as rheumatoid arthritis and lupus, which are also areas of research for institutions like the University of California, San Diego and the Johns Hopkins University School of Medicine. The company's work is also related to the research of scientists like Barry Bloom and Emil Unanue, who have made significant contributions to the field of immunology.

Financial Information

Omeros is a publicly traded company listed on the NASDAQ stock exchange, and its financial information is available through its annual and quarterly reports, which are filed with the Securities and Exchange Commission. The company has a market capitalization of over $1 billion and has a diverse investor base, including institutions like Fidelity Investments and Vanguard Group. Omeros has also received funding from organizations like the National Institutes of Health and the Bill and Melinda Gates Foundation, and has collaborations with companies like Pfizer and Merck & Co.. The company's financial performance is also influenced by the performance of the biotechnology industry as a whole, which is affected by factors like the US Food and Drug Administration's approval process and the patent landscape, and is related to the work of organizations like the Biotechnology Innovation Organization and the Pharmaceutical Research and Manufacturers of America. Category:Biotechnology companies